These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22309319)

  • 1. Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
    Cytotherapy; 2012 Apr; 14(4):505-12. PubMed ID: 22309319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
    Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
    Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating CD3
    Lee SE; Lim JY; Ryu DB; Kim TW; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Min CK
    Biomed Res Int; 2018; 2018():5097325. PubMed ID: 29511683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kinetic study on the variety of lymphocytes and CD34+ cell subsets during autologous peripheral blood stem cell transplantation].
    Han XH; Shi YK; He XH; Yang JL; Liu P
    Zhonghua Zhong Liu Za Zhi; 2003 Jan; 25(1):47-50. PubMed ID: 12678987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.
    Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D
    Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma.
    Porrata LF; Gertz MA; Geyer SM; Litzow MR; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Lacy MQ; Dispenzieri A; Snow DS; Markovic SN
    Leukemia; 2004 Jun; 18(6):1085-92. PubMed ID: 15042106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation.
    Schnabel B; Schmidmaier R; Franke D; Emmerich B; Straka C
    Cytotherapy; 2006; 8(5):473-9. PubMed ID: 17050252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
    Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
    Millar BC; Bell JB; Powles RL
    Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients.
    Laurenti L; Piccioni P; Piccirillo N; Sora' F; Chiusolo P; Garzia M; Reddiconto G; De Matteis S; Tarnani M; Leone G; Sica S
    Leuk Lymphoma; 2004 Oct; 45(10):2063-70. PubMed ID: 15370251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts.
    Theilgaard-Mönch K; Raaschou-Jensen K; Palm H; Schjødt K; Heilmann C; Vindeløv L; Jacobsen N; Dickmeiss E
    Bone Marrow Transplant; 2001 Dec; 28(11):1073-82. PubMed ID: 11781619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
    Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
    Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
    Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
    Rueff J; Medinger M; Heim D; Passweg J; Stern M
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.